Parkinson’s disease management and impulse control disorders: current state and future perspectives

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
   Google Scholar
• Weintraub D, David AS, Evans AH, et al. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30:121–127.
   PubMed Web of Science ®Google Scholar
• Dagher A, Robbins TW. Personality, addiction, dopamine: insights from Parkinson’s disease. Neuron. 2009;61(4):502–510.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63:969–973.
   PubMed Web of Science ®Google Scholar
• Voon V, Fox SH. Medication-related impulse control and repetitive behaviours in Parkinson’s disease. Arch Neurol. 2007;64:1089–1096.
   PubMedGoogle Scholar
• Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589–595.
   PubMed Web of Science ®Google Scholar
• Voon V, Reynolds B, Brezing C, et al. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology (Berl). 2010;207:645–659.
   PubMed Web of Science ®Google Scholar
• Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case–control study. Ann Neurol. 2011;69:986–996.
   PubMed Web of Science ®Google Scholar
• Marques A, Durif F, Fernagut PO. Impulse control disorders in Parkinson’s disease. J Neural Transm (Vienna). 2018;125(8):1299–1312.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, O’Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68:423–428.
   PubMed Web of Science ®Google Scholar
• Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord. 2004;19:397–405.
   PubMed Web of Science ®Google Scholar
• Evans AH, Lawrence AD, Potts J, et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology. 2005;65:1570–1574.
   PubMed Web of Science ®Google Scholar
• Raja M, Bentivoglio AR. Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson’s disease and other disorders. Curr Drug Saf. 2012;7:63–75.
   PubMedGoogle Scholar
• Evans AH, Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord. 2007;22:590–591.
   PubMed Web of Science ®Google Scholar
• Wicks P, Macphee GJ. Pathological gambling amongst Parkinson’s disease and ALS patients in an online community (PatientsLikeMe.com). Mov Disord. 2009;24:1085–1088.
   PubMed Web of Science ®Google Scholar
• Voon V, Schoerling A, Wenzel S, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011;11:117.
   PubMed Web of Science ®Google Scholar
• Samuel M, Rodriguez-Oroz M, Antonini A, et al. Management of impulse control disorders in Parkinson’s disease: controversies and future approaches. Mov Disord. 2015;30(2):150–159.
   PubMed Web of Science ®Google Scholar
• Marques A, Figorilli M, Pereira B, et al. Impulse control disorders in Parkinson’s disease patients with RLS: a cross sectional-study. Sleep Med. 2018;48:148–154.
   PubMed Web of Science ®Google Scholar
• Molde H, Moussavi Y, Kopperud ST, et al. Impulse-control disorders in Parkinson’s disease: a meta-analysis and review of case-control studies. Front Neurol. 2018;9:330.
   PubMed Web of Science ®Google Scholar
• Vitale C, Santangelo G, Trojano L, et al. Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson’s disease. Mov Disord. 2011;26(5):830–836.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Vitale C, Trojano L, et al. Cognitive dysfunctions and pathological gambling in patients with Parkinson’s disease. Mov Disord. 2009;24(6):899–905.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Barone P, Trojano L, et al. Pathological gambling in Parkinson’s disease. A comprehensive review. Parkinsonism Relat Disord. 2013;19(7):645–653.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Piscopo F, Barone P, et al. Personality in Parkinson’s disease: clinical, behavioural and cognitive correlates. J Neurol Sci. 2017;374:17–25.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Garramone F, Baiano C, et al. Personality and Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord. 2018;49:67–74.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Papay K, Siderowf A, Parkinson’s Progression Markers Initiative. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology. 2013;80(2):176–180.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Trojano L, Barone P, et al. Impulse control disorders and cognitive dysfunctions in patients with Parkinson’s disease. Neurol Sci. 2013;34(11):2045–2046.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Raimo S, Barone P. The relationship between impulse control disorders and cognitive dysfunctions in Parkinson’s disease: a meta-analysis. Neurosci Biobehav Rev. 2017;77:129–147.
   PubMed Web of Science ®Google Scholar
• Scullin MK, Sollinger AB, Land J, et al. Sleep and impulsivity in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:991–994.
   PubMed Web of Science ®Google Scholar
• Fantini ML, Macedo L, Zibetti M, et al. Increased risk of impulse control symptoms in Parkinson’s disease with REM sleep behaviour disorder. J Neurol Neurosurg Psychiatry. 2015;86(2):174–179.
   PubMed Web of Science ®Google Scholar
• Fantini ML, Figorilli M, Arnulf I, et al. Sleep and REM sleep behaviour disorder in Parkinson’s disease with impulse control disorder. J Neurol Neurosurg Psychiatry. 2018;89(3):305–310.
   PubMed Web of Science ®Google Scholar
• Cormier F, Muellner J, Corvol JC. Genetics of impulse control disorders in Parkinson’s disease. J Neural Transm. 2013;120:665–671.
   PubMed Web of Science ®Google Scholar
• Erga AH, Dalen I, Ushakova A, et al. Dopaminergic and opioid pathways associated with impulse control disorders in Parkinson’s disease. Front Neurol. 2018;9:109.
   PubMed Web of Science ®Google Scholar
• Morgante F, Fasano A, Ginevrino M, et al. Impuulsive-compulsive behaviors in parkin assoicated parkinson’s disesae. Neurol. 2016;87(14):1436–1441.
   PubMed Web of Science ®Google Scholar
• Balarajah S, Cavanna AE. The pathophysiology of impulse control disorders in Parkinson disease. Behav Neurol. 2013;26:237–244.
   PubMed Web of Science ®Google Scholar
• Cilia R, Bao L, Andre P, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol Dis. 2010;39:98–104.
   PubMed Web of Science ®Google Scholar
• Cilia R, Cho SS, van Eimeren T, et al. Pathological gambling in patients with Parkinson’s disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord. 2011;26:225–233.
   PubMed Web of Science ®Google Scholar
• Aracil-Bolaños I, Strafella AP. Molecular imaging and neural networks in impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2016;22(Suppl1):S101–S105.
   PubMedGoogle Scholar
• Tessitore A, Santangelo G, De Micco R, et al. Cortical thickness changes in patients with Parkinson’s disease and impulse control disorders. Parkinsonism Relat Disord. 2016;24:119–125.
   PubMed Web of Science ®Google Scholar
• Tessitore A, Santangelo G, De Micco R, et al. Resting-state brain networks in patients with Parkinson’s disease and impulse control disorders. Cortex. 2017;94:63–72.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Trojano L, Barone P, et al. Cortical thickness in Parkinsonians with impulse control disorders: a comment. Mov Disord. 2015;30(9):1293.
   PubMed Web of Science ®Google Scholar
• Tanwani P, Fernie BA, Nikčević AV, et al. A systematic review of treatments for impulse control disorders and related behaviours in Parkinson’s disease. Psychiatry Res. 2015;225(3):402–406.
   PubMed Web of Science ®Google Scholar
• Ramirez-Zamora A, Gee L, Boyd J, et al. Treatment of impulse control disorders in Parkinson’s disease: practical considerations and future directions. Expert Rev Neurother. 2016;16(4):389–399.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Claassen DO. Impulse Control and Related Disorders in Parkinson's Disease. Int Rev Neurobiol. 2017;133:679-717. doi: 10.1016/bs.irn.2017.04.006.
   Google Scholar
• Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson’s disease: review. Ann N Y Acad Sci. 2008;1142:85–107.
   PubMed Web of Science ®Google Scholar
• Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med. 1988;318:876–880.
   PubMed Web of Science ®Google Scholar
• Swainson R, Rogers RD, Sahakian BJ, et al. Probabilistic learning and reversal deficits in patients with Parkinson’s disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia. 2000;38:596–612.
   PubMed Web of Science ®Google Scholar
• Paulson PE, Robinson TE. Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats. Synapse. 1995;19:56–65.
   PubMed Web of Science ®Google Scholar
• Bordet R, Ridray S, Carboni S, et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A. 1997;94:3363–3367.
   PubMed Web of Science ®Google Scholar
• Sokoloff P, Diaz J, Le Foll B, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Target. 2006;5:25–43.
   PubMedGoogle Scholar
• Pilla M, Perachon S, Sautel F, et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature. 1999;400:371–375.
   PubMed Web of Science ®Google Scholar
• Accili D, Fishburn CS, Drago J, et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA. 1996;93:1945–1949.
   PubMed Web of Science ®Google Scholar
• Singh A, Kandimala G, Dewey RB Jr, et al. Risk factors for pathological gambling and other compulsion among Parkinson’s disease patients taking dopamine agonists. J Clin Neurosci. 2007;14:1178–1181.
   PubMed Web of Science ®Google Scholar
• Mamikonyan E, Siderowf AD, Duda JE, et al. Long term follow up of impulse control disorders in Parkinson’s disease. Mov Disord. 2008;23:75–80.
   PubMed Web of Science ®Google Scholar
• Sohtaoglu M, Demiray DY, Kenangil G, et al. Long term follow-up of Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2010;16:334–337.
   PubMed Web of Science ®Google Scholar
• Kimber TE, Thompson PD, Kiley MA. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonists therapy in Parkinson’s disease. J Clin Neurosci. 2008;15:205–208.
   PubMed Web of Science ®Google Scholar
• Vitale C, Santangelo G, Verde F, et al. Exercise dependence induced by pramipexole in Parkinson’s disease-a case report. Mov Disord. 2010;25:2893–2894.
   PubMed Web of Science ®Google Scholar
• Vitale C, Trojano L, Barone P, et al. Compulsive drumming induced by dopamine agonists treatment in Parkinson’s disease: another aspect of punding. Behav Neurol. 2013;27:559–5623.
   PubMed Web of Science ®Google Scholar
• Solla P, Cannas A, Marrosu MG, et al. Dopaminergic-induced paraphilias associated with impulse control and related disorders in patients with Parkinson disease. J Neurol. 2012;259:2752–2754.
   PubMed Web of Science ®Google Scholar
• Giugni JC, Tschopp L, Escalante V, et al. Dose-dependent impulse control disorders in piribedil overdose. Clin Neuropharmacol. 2012;35:49–50.
   PubMed Web of Science ®Google Scholar
• Ramírez Gómez CC, Serrano Dueñas M, Bernal O, et al. A multicenter comparative study of impulse control disorder in Latin American patients with Parkinson disease. Clin Neuropharmacol. 2017;40(2):51–55.*.
   PubMed Web of Science ®Google Scholar
• Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67:58–63.
   PubMed Web of Science ®Google Scholar
• Rizos A, Sauerbier A, Antonini A, et al., EUROPAR and the IPMDS Non-Motor-PD-Study Group. A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016;23(8):1255–1261.
   PubMed Web of Science ®Google Scholar
• Antonini A, Asgharnejad M, Bauer L, et al. Incidence of impulsive and compulsive behavior type adverse events with long-term rotigotine: a post-hoc analysis (I3-5E). Neurology. 2015;84:I3–5E.
   Google Scholar
• Corvol JC, Artaud F, Cormier-Dequaire F, et al., DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91(3):189–201.
   PubMed Web of Science ®Google Scholar
• Kon T, Ueno T, Haga R, et al. The factors associated with impulse control behaviors in Parkinson’s disease: a 2-year longitudinal retrospective cohort study. Brain Behav. 2018;8(8):e01036.
   PubMed Web of Science ®Google Scholar
• Cunnington AL, White L, Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:1051–1052.
   PubMed Web of Science ®Google Scholar
• Pondal M, Marras C, Miyasaki J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry. 2013;84:130–135.
   PubMed Web of Science ®Google Scholar
• Patel S, Garcia X, Mohammad ME, et al. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center. J Neurol Sci. 2017;379:308–311.
   PubMed Web of Science ®Google Scholar
• Yu XX, Fernandez HH. Dopamine agonist withdrawal syndrome: a comprehensive review. J Neurol Sci. 2017;374:53–55.
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840–844.
   PubMed Web of Science ®Google Scholar
• Garcia X, Patel S, Mohammad ME, et al. Higher doses of dopamine agonists, impulse control disorders and history of deep brain stimulation (DBS): risk factors for dopamine agonists withdrawal syndrome (DAWS)?. Mov Disord. 2016;31(Suppl. 2).
   PubMedGoogle Scholar
• Stamey W, Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008;14(2):89–99.
   PubMed Web of Science ®Google Scholar
• Potenza MN, Voon V, Weintraub D. Drug insight: impulse control disorders and dopamine therapies in Parkinson’s disease. Nat Clin Pract Neurol. 2007;3(12):664–672.
   PubMedGoogle Scholar
• Carvalho MM, Campos FL, Marques M, et al. Effect of levodopa on reward and Impulsivity in a rat model of Parkinson’s disease. Front Behav Neurosci. 2017;11:145.
   PubMed Web of Science ®Google Scholar
• Pontone G, Williams JR, Basset SS, et al. Clinical features associated with impulse control disorders in Parkinson’s disease. Neurology. 2006;67:1258–1261.
   PubMed Web of Science ®Google Scholar
• Avanzi M, Uber E, Bonfà F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson’s disease. Neurol Sci. 2004;25:98–101.
   PubMed Web of Science ®Google Scholar
• Goodwin FK. Psychiatric side effects of levodopa in man. JAMA. 1971;218:1915–1920.
   PubMed Web of Science ®Google Scholar
• Tyne HL, Medley G, Ghadiali E, et al. Gambling in Parkinson’s disease. Mov Disord. 2004;19(Suppl. 9):S195.
   Google Scholar
• Antonini A, Barone P, Bonuccelli U, et al. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(4):317–324. .
   PubMed Web of Science ®Google Scholar
• Bastiaens J, Dorfman BJ, Christos PJ, et al. Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord. 2013;28(3):327–333.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346–356.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35:261–265.
   PubMed Web of Science ®Google Scholar
• Vitale C, Santangelo G, Erro R, et al. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson’s disease: report of 2 cases. Parkinsonism Relat Disord. 2013;19(4):483–484.
   PubMed Web of Science ®Google Scholar
• Reyes D, Kurako K, Galvez-Jimenez N. Rasagiline induced hypersexuality in Parkinson’s disease. J Clin Neurosci. 2014;21:507–508.
   PubMed Web of Science ®Google Scholar
• Levy A, Lang AE. Recurrent impulse control disorder associated with rasagiline treatment of Parkinson’s Disease. Can J Neurol Sci. 2017;44(4):447–448.
   PubMed Web of Science ®Google Scholar
• Drapier D, Drapier S, Sauleau P, et al. Pathological gambling secondary to dopaminergic therapy in Parkinson’s disease. Psychiatry Res. 2006;144:241–244.
   PubMed Web of Science ®Google Scholar
• Vevera J, Stopkova R, Bes M, et al. COMT polymorphisms in impulsively violent offenders with antisocial personality disorder. Neuro Endocrinol Lett. 2009;30(6):753–756.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery? J Neural Transm. 2013;12:1305–1320.
   Google Scholar
• Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24:1468–1474.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin PRP, Antonini A, Henriksen T, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared with conventional therapy: a real life study of non-motor effect. J Park Dis. 2011;1:197–203.
   Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90–99.
   PubMed Web of Science ®Google Scholar
• Macphee GJ, Chaudhuri KR, David AS, et al. Managing impulse control behaviours in Parkinson’s disease: practical guidelines. Br J Hosp Med. 2013;74(3):160–166.
   Web of Science ®Google Scholar
• Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol. 2009;8:929–937.
   PubMed Web of Science ®Google Scholar
• Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug Saf. 2009;32:475–488.
   PubMed Web of Science ®Google Scholar
• Grosset K, Needleman F, Macphee G, et al. Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: a clinical series and five-drug dose conversion table. Mov Disord. 2004;19:1370–1374.
   PubMed Web of Science ®Google Scholar
• Antonini A. Continuous dopaminergic stimulation–from theory to clinical practice. Parkinsonism Relat Disord. 2007;13(Suppl.):S24–S28.
   PubMedGoogle Scholar
• Todorova A, Ray Chaudhuri K. Subcutaneous apomorphine and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(12):1073–1078.
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicentre study. Mov Disord. 2008;23(8):1130–1136.
   PubMed Web of Science ®Google Scholar
• Magennis B, Cashell A, O’Brien D, et al. An audit of apomorphine in the management of complex idiopathic Parkinson’s disease in Ireland. Mov Disord. 2012;27(Suppl 1):S44.
   Google Scholar
• Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30:510–516.
   PubMed Web of Science ®Google Scholar
• Todorova A, Samuel M, Brown RG, et al. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years’ Follow-up. Clin Neuropharmacol. 2015;38(4):132–134.
   PubMed Web of Science ®Google Scholar
• Catalan MJ, de Pablo-Fernandez E, Villanueva C, et al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson’s disease. Mov Disord. 2013;28:2007–2010.
   PubMedGoogle Scholar
• Gerschlager W, Bloem BR. Managing pathological gambling in Parkinson’s disease with enteral levodopa/carbidopa infusions. Mov Disord. 2009;24:1858–1860.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–149.
   PubMed Web of Science ®Google Scholar
• Chang FC, Kwan V, van der Poorten D, et al. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease. J Clin Neurosci. 2016;25:41–45.
   PubMed Web of Science ®Google Scholar
• Catalan MJ, Molina-Arjona JA, Mir P, EDIS Study Group, et al. Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease. J Neurol. 2018;265(6):1279–1287.
   PubMed Web of Science ®Google Scholar
• Adams WK, Vonder Haar C, Tremblay M, et al. Deep-brain stimulation of the subthalamic nucleus selectively decreases risky choice in risk-preferring rats. eNeuro. 2017 Aug 7;4(4).
   Web of Science ®Google Scholar
• Breysse E, Pelloux Y, Baunez C. The good and bad differentially encoded within the subthalamic nucleus in rats(1,2,3). eNeuro. 2015;2.
   PubMed Web of Science ®Google Scholar
• Tachibana Y, Hikosaka O. The primate ventral pallidum encodes expected reward value and regulates motor action. Neuron. 2012;76:826–837.
   PubMed Web of Science ®Google Scholar
• Hong S, Hikosaka O. Diverse sources of reward value signals in the basal ganglia nuclei transmitted to the lateral habenula in the monkey. Front Hum Neurosci. 2013;7:778.
   PubMed Web of Science ®Google Scholar
• Espinosa-Parrilla JF, Baunez C, Apicella P. Modulation of neuronal activity by reward identity in the monkey subthalamic nucleus. Eur J Neurosci. 2015;42:1705–1717.
   PubMed Web of Science ®Google Scholar
• Howell NA, Prescott IA, Lozano AM, et al. Preliminary evidence for human globus pallidus pars interna neurons signaling reward and sensory stimuli. Neuroscience. 2016;328:30–39.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Oroz MC, López-Azcárate J, Garcia-Garcia D, et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson’s disease. Brain. 2011;134(Pt1):36–49.
   PubMedGoogle Scholar
• Rosa M, Fumagalli M, Giannicola G, et al. Pathological gambling in Parkinson’s disease: subthalamic oscillations during economics decisions. Mov Disord. 2013;28(12):1644–1652.
   PubMed Web of Science ®Google Scholar
• Rossi PJ, Shute JB, Opri E, et al. Impulsivity in Parkinson’s disease is associated with altered subthalamic but not globus pallidus internus activity. J Neurol Neurosurg Psychiatry. 2017;88(11):968–970.
   PubMed Web of Science ®Google Scholar
• Lhommée E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours. Brain. 2012;135(Pt5):1463–1477.
   PubMedGoogle Scholar
• Gee L, Smith H, De La Cruz P, et al. The influence ofBilateral subthalamic nucleus deep brain stimulation on impulsivity and prepulse inhibition in Parkinson’s disease Patients. Stereotact Funct Neurosurg. 2015;93(4):265–2670.
   PubMed Web of Science ®Google Scholar
• Castrioto A, Funkiewiez A, Debû B, et al. Iowa gambling task impairment in Parkinson’s disease can be normalised by reduction of dopaminergic medication after subthalamic stimulation. J Neurol Neurosurg Psychiatry. 2015;86(2):186–190.
   PubMed Web of Science ®Google Scholar
• Amami P, Dekker I, Piacentini S, et al. Impulse control behaviours in patients with Parkinson’s disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. J Neurol Neurosurg Psychiatry. 2015;86(5):562–564.
   PubMed Web of Science ®Google Scholar
• Lhommée E, Boyer F, Wack M, et al. Personality, dopamine, and Parkinson’s disease: insights from subthalamic stimulation. Mov Disord. 2017;32(8):1191–1200.
   PubMed Web of Science ®Google Scholar
• Merola A, Romagnolo A, Rizzi L, et al. Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease. J Neurol. 2017;264(1):40–48.
   PubMed Web of Science ®Google Scholar
• Lhommée E, Wojtecki L, Czernecki V, EARLYSTIM study group, et al. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol. 2018;17(3):223–231.
   PubMed Web of Science ®Google Scholar
• Kim A, Kim YE, Kim HJ, et al. A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2018;56:3–8.
   Web of Science ®Google Scholar
• Abbes M, Lhommée E, Thobois S, et al. Subthalamic stimulation and neuropsychiatric symptoms in Parkinson’s disease: results from a long-term follow-up cohort study. J Neurol Neurosurg Psychiatry. 2018;89(8):836–843.
   PubMed Web of Science ®Google Scholar
• Eusebio A, Witjas T, Cohen J, et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2013;84(8):868–874.
   PubMed Web of Science ®Google Scholar
• Kim YE, Kim HJ, Kim HJ, et al. Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson’s disease. J Clin Neurosci. 2013;20(7):964–969.
   PubMed Web of Science ®Google Scholar
• Moum SJ, Price CC, Limotai N, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One. 2012;7(1):e29768.
   PubMed Web of Science ®Google Scholar
• Umemura A, Oka Y, Yamamoto K, et al. Complications of subthalamic nucleus stimulation in Parkinson’s disease. Neurol Med Chir (Tokyo). 2011;51(11):749–755.
   PubMed Web of Science ®Google Scholar
• Hack N, Akbar U, Thompson-Avila A, et al. Impulsive and compulsive behaviors in Parkinson Study Group (PSG) centers performing deep brain stimulation surgery. J Parkinsons Dis. 2014;4(4):591–598.
   PubMedGoogle Scholar
• Kasemsuk C, Oyama G, Hattori N. Management of impulse control disorders with deep brain stimulation: a double-edged sword. J Neurol Sci. 2017;374:63–68.
   PubMed Web of Science ®Google Scholar
• Hälbig TD, Tse W, Frisina PG, et al. Subthalamic deep brain stimulation and impulse control in Parkinson’s disease. Eur J Neurol. 2009;16(4):493–497.
   PubMed Web of Science ®Google Scholar
• Brandt J, Rogerson M, Al-Joudi H, et al. Betting on DBS: effects of subthalamic nucleus deep brain stimulation on risk taking and decision making in patients with Parkinson’s disease. Neuropsychology. 2015;29(4):622–631.
   PubMed Web of Science ®Google Scholar
• Frank MJ, Samanta J, Moustafa AA, et al. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science. 2007;318(5854):1309–1312.
   PubMed Web of Science ®Google Scholar
• Mallet L, Schüpbach M, N’Diaye K, et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci USA. 2007;104(25):10661–10666.
   PubMed Web of Science ®Google Scholar
• Ballanger B, van Eimeren T, Moro E, et al. Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol. 2009;66:817–824.
   PubMed Web of Science ®Google Scholar
• Aiello M, Eleopra R, Foroni F, et al. Weight gain after STN-DBS: the role of reward sensitivity and impulsivity. Cortex. 2017;92:150–161.
   PubMed Web of Science ®Google Scholar
• Zahodne LB, Susatia F, Bowers D, et al. Binge eating in Parkinson’s disease: prevalence,correlates and the contribution of deep brain stimulation. J Neuropsychiatry Clin Neurosci. 2011;23(1):56–62.
   PubMed Web of Science ®Google Scholar
• Lim S, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson’s disease. Ann N Y Acad Sci. 2008;1142:85–197.
   PubMed Web of Science ®Google Scholar
• Delaney M, Leroi I, Simpson J, et al. Impulse control disorders in Parkinson’s disease: a psychosocial perspective. J Clin Psychol Med Settings. 2012;19(3):338–346.
   PubMed Web of Science ®Google Scholar
• Kurlan R. Disabling repetitive behaviors in Parkinson’s disease. Mov Disord. 2004;19(4):433–437.
   PubMed Web of Science ®Google Scholar
• Zhang S, Dissanayaka NN, Dawson A, et al. Management of impulse control disorders in Parkinson’s disease. Int Psychogeriatr. 2016;28(10):1597–1614.
   PubMed Web of Science ®Google Scholar
• Jiménez-Murcia S, Bove FI, Israel M, et al. Cognitive-behavioral therapy for pathological gambling in Parkinson’s disease: a pilot controlled study. Eur Addict Res. 2012;18(6):265–274.
   PubMed Web of Science ®Google Scholar
• Koychev I, Okai D. Cognitive-behavioural therapy for non-motor symptoms of Parkinson’s disease: a clinical review. Evid Based Ment Health. 2017;20(1):15–20.
   PubMed Web of Science ®Google Scholar
• Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. 2013;80:792–799.
   PubMed Web of Science ®Google Scholar
• Okai D, Askey-Jones S, Samuel M, et al. Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson’s disease. Mov Disord. 2015;30:736–739.
   PubMed Web of Science ®Google Scholar
• Fattore L, Spano M, Melis V, et al. Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats. Br J Pharmacol. 2011;163:1550–1562.
   PubMed Web of Science ®Google Scholar
• Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA. 1998;95:9608–9613.
   PubMed Web of Science ®Google Scholar
• Mitchell JM, O’Neil JP, Jagust WJ, et al. Catechol-O-methyltransferase genotype modulates opioid release in decision circuitry. Clin Transl Sci. 2013;6:400–403.
   PubMed Web of Science ®Google Scholar
• Scott D, Taylor JR. Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task. Behav Brain Res. 2014;259:164–173.
   PubMed Web of Science ®Google Scholar
• Albrecht B, Brandeis D, von Sandersleben HU, et al. Genetics of preparation and response control in ADHD: the role of DRD4 and DAT1. J Child Psychol Psychiatry. 2014;55:914–923.
   PubMed Web of Science ®Google Scholar
• Visanji NP, Fox SH, Johnston TH, et al. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. J Pharmacol Exp Ther. 2009;328:276–283.
   PubMed Web of Science ®Google Scholar
• Johnston TH, Fox SH, McIldowie MJ, et al. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease. J Pharmacol Exp Ther. 2010;333:865–873.
   PubMed Web of Science ®Google Scholar
• Huot P, Johnston TH, Koprich JB, et al. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease. J Pharmacol Exp Ther. 2012;342:576–585.
   PubMed Web of Science ®Google Scholar
• Hamilton J, Lee J, Canales JJ. Chronic unilateral stimulation of the nucleus accumbensat high or low frequencies attenuates relapse to cocaine seeking in an animal model. Brain Stimul. 2015;8(1):57–63.
   PubMed Web of Science ®Google Scholar
• Nardone R, De Blasi P, Höller Y, et al. Repetitive transcranial magnetic stimulation transiently reduces punding in Parkinson’s disease: a preliminary study. J Neural Transm (Vienna). 2014;121(3):267–274.
   PubMed Web of Science ®Google Scholar
• Bechara A, Van Der Linden M. Decision-making and impulse control after frontal lobe injuries. Curr Opin Neurol. 2005;18(6):734–739.
   PubMed Web of Science ®Google Scholar